Verda Bio

An organic-equivalent standard remained elusive, but a WSDA official and WSU researcher offered ideas regarding hemp and cannabis regulation before responding to attendee comments.

As WSLCB staff worked to make progress on medical cannabis rulemaking, regulators from across the country would convene in Minneapolis to engage with “External Stakeholders.”

The work group discussed two questions: was it possible to define “high THC” products, and were there gaps in requirements on cannabis product stability?

After a full week of WSLCB board activity, the Cannabis Alliance planned to host the ninth annual Washington State Cannabis Summit to engage with contemporary cannabis issues.

Efforts to draft improved cannabis testing and additive rules drew skepticism and questions from attendees worried about testing standards, synthetic cannabinoids, enforcement, and more.

Staff went over a reorganization at WSDA including hemp and cannabis programs; the transition of lab standards and accreditation authority; plus tips for hemp licensees.

In looking at rulemaking implementing definitional and retail medical endorsement changes, various parties were interested in impacts for producing and selling hemp consumables in 502.

Officials outlined a transition period to take on accreditation authority in parallel with revising standards, including method approval and when enforcement of new standards would start.

DOH staff heard stories and suggestions from patients, advocates, and other stakeholders on how to improve affordability, access, and understanding of medically compliant cannabis products.

Staff heard from a few attendees with lab experience about potential changes in rule from SB 5367, focusing on definitions for THC content and synthesized cannabinoids.